曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述

• 药物经济学 • 上一篇

曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述

马林超,刘永军

中国药科大学,中国药科大学

收稿日期:2014-04-22 修回日期:2014-06-03 出版日期:2014-08-25 发布日期:2014-08-25

Pharmacoeconomic Evaluation on Trastuzumab in adjuvant breast cancer therapy for HER2-Positive Breast Cancer: A Systematic Review

China Pharmaceutical University,

Received:2014-04-22 Revised:2014-06-03 Online:2014-08-25 Published:2014-08-25

摘要/Abstract

摘要： 目的：对曲妥珠单抗联合化疗治疗HER2阳性乳腺癌的药物经济学进行系统分析。方法：计算机检索PubMed、ScienceDirect、SpringerLink等数据库2003—2013年间已发表的药物经济学文献，按照一定标准进行筛选，根据药物经济学方法，进行系统综述。结果：曲妥珠单抗治疗的增量成本效果比（ICER）值美国在34307~126933美元每QALY之间，瑞典为35975~52753欧元每QALY，挪威每一个LYS需要多付出8148~162417欧元，日本为17000欧元每LYG。结论：曲妥珠单抗联合化疗治疗HER2阳性乳腺癌是否具有经济性的研究结论不一致。在15篇研究中，有4篇研究认为曲妥珠单抗联合化疗方案不具有成本效果。

Abstract: Objective: To systematically evaluate the pharmacoeconomic vaule of Trastuzumab in adjuvant breast cancer therapy for HER2-Positive Breast Cancer. Methods:A systematic literature search of cost-effectiveness studies on Trastuzumab in adjuvant breast cancer therapy for HER2-Positive Breast Cancer published from 2003 to 2013 was carried out in PubMed, ScienceDirect, SpringerLink and some other database. The studies were screened according to inclusion criteria and the systematic review was conducted according to Pharmacoeconomic methods. Results: The ICER of Trastuzumab in adjuvant breast cancer therapy for HER2-Positive Breast Cancer was $ 34307~126933 /QALY in America, and €35975~52753/QALY in Sweden, €8148~162417/LYS in Norway and €17000/LYG in Japan. Conclusion: Studies concerning the cost-effectiveness of traztuzumab for HER2 positive breast cancer patients have not reached consistent conclusions. In the 15 literatures included, 4 of them concluded that Trastuzumab is not a cost-effective therapy with ICER above the implemented willingness-to-pay thresholds.

马林超,刘永军. 曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述[J]. .